Exenatide

CAS 141758-74-9 6 current records 3 historicalProtein

Who holds supplier records for Exenatide? 6 organisations hold a current record for Exenatide: an active US FDA Type II Drug Master File. A further 3 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (2), Sweden (1), Belgium (1) and Netherlands (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records

Cite as: PharmaTek, “Exenatide: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/exenatide

Reading the evidence

  • 6 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 3 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (6)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Exenatide. Country is the organisation's recorded country, not necessarily the manufacturing site.

India2Sweden1Belgium1Netherlands1Country not recorded for 1
  • PolyPeptide Laboratories (Sweden) AB
    Active DMF 30924, 27714 · latest filing Sept 2016
    Sweden Company GMP cert on record
  • ALP PHARM BEIJING CO LTD
    Active DMF 35476 · latest filing Dec 2020
  • MSN LIFE SCIENCES PRIVATE LIMITED
    Active DMF 34566 · latest filing Feb 2020
    India Company GMP cert on record
  • Polypeptide
    Active DMF 19646 · latest filing Jul 2006
    Belgium
  • Sun Pharmaceutical Industries Limited
    Active DMF 29863 · latest filing Dec 2015
    India Company GMP cert on record
  • TAPI NL BV
    Active DMF 27123 · latest filing Jul 2013
    Netherlands
Need Exenatide sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (3)

Organisations whose Type II DMFs for Exenatide are no longer active. These show a past filing, not current supply.

Show all 3 historical records
  • BACHEM AMERICAS INC
    Inactive DMF 17227 · filed Mar 2004
  • United States · Inactive DMF 17114 · filed Jan 2004
  • MALLINCKRODT INC
    Inactive DMF 13932 · filed Jan 1999

Overview

Exenatide is a protein active pharmaceutical ingredient (ChEMBL CHEMBL414357).

Chemical identity

IUPAC name
(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
Canonical SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC9=CN=CN9)N
InChIKey
HTQBXNHDCUEHJF-XWLPCZSASA-N
Synonyms
AC-002993, AC002993, AC 2993, AC-2993, AC2993, AC-2993A, AC2993A, AC-2993LAR, Bydureon, Bydureon bcise, Bydureon pen, Byetta

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
GLP-1 Receptor Agonist
Mechanism of action
Glucagon-like Peptide-1 (GLP-1) Agonists
Chemical structure
Glucagon-Like Peptide 1

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Exenatide?

6 organisations hold an active US FDA Type II Drug Master File or a CEP for Exenatide: PolyPeptide Laboratories (Sweden) AB (Sweden), ALP PHARM BEIJING CO LTD, MSN LIFE SCIENCES PRIVATE LIMITED (India), Polypeptide (Belgium), Sun Pharmaceutical Industries Limited (India) and TAPI NL BV (Netherlands). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Exenatide Drug Master Files are active?

PolyPeptide Laboratories (Sweden) AB (DMF 30924, 27714), ALP PHARM BEIJING CO LTD (DMF 35476), MSN LIFE SCIENCES PRIVATE LIMITED (DMF 34566), Polypeptide (DMF 19646), Sun Pharmaceutical Industries Limited (DMF 29863) and TAPI NL BV (DMF 27123). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Exenatide records mean?

3 organisations have only inactive Type II DMFs for Exenatide. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

How do I qualify a Exenatide supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Exenatide?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.